Efficacy and safety of pyrotinib-based regimens in patients with HER2-positive stage III/IV breast cancer: a real-world retrospective study in China
Pyrotinib-based regimens have shown satisfactory clinical efficacy in HER2-positive stage III/IV BC patients, and pyrotinib is well tolerated with manageable adverse events.
Authors
- Lei Yu (ORCID: https://orcid.org/0000-0003-0010-9228)
- Lei Huang (ORCID: https://orcid.org/0000-0003-2458-5149)
- Qiong Wu
- Limin Zhi
- Xiaohong Pang
Institutions
- The People's Hospital of Guangxi Zhuang Autonomous Region (CN)
- Tumor Hospital of Guangxi Medical University (CN)
Publication Details
- Journal
- PeerJ
- Published
- 2026-01-13
- DOI
- https://doi.org/10.7717/peerj.20524
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00